• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用受控衰减参数和1H-磁共振波谱对非酒精性脂肪性肝病患者的肝脂肪变性进行无创评估。

Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy.

作者信息

Karlas Thomas, Petroff David, Garnov Nikita, Böhm Stephan, Tenckhoff Hannelore, Wittekind Christian, Wiese Manfred, Schiefke Ingolf, Linder Nicolas, Schaudinn Alexander, Busse Harald, Kahn Thomas, Mössner Joachim, Berg Thomas, Tröltzsch Michael, Keim Volker, Wiegand Johannes

机构信息

IFB AdiposityDiseases, Leipzig University Medical Center, Leipzig, Germany; Department of Medicine, Neurology and Dermatology, Division of Gastroenterology and Rheumatology, University Hospital Leipzig, Leipzig, Germany.

IFB AdiposityDiseases, Leipzig University Medical Center, Leipzig, Germany; Clinical Trial Center, University of Leipzig, Leipzig, Germany.

出版信息

PLoS One. 2014 Mar 17;9(3):e91987. doi: 10.1371/journal.pone.0091987. eCollection 2014.

DOI:10.1371/journal.pone.0091987
PMID:24637477
原文链接:
https://pmc.ncbi.nlm.nih.gov/articles/PMC3956815/
Abstract

INTRODUCTION

Non-invasive assessment of steatosis and fibrosis is of growing relevance in non-alcoholic fatty liver disease (NAFLD). 1H-Magnetic resonance spectroscopy (1H-MRS) and the ultrasound-based controlled attenuation parameter (CAP) correlate with biopsy proven steatosis, but have not been correlated with each other so far. We therefore performed a head-to-head comparison between both methods.

METHODS

Fifty patients with biopsy-proven NAFLD and 15 healthy volunteers were evaluated with 1H-MRS and transient elastography (TE) including CAP. Steatosis was defined according to the percentage of affected hepatocytes: S1 5-33%, S2 34-66%, S3 ≥67%.

RESULTS

Steatosis grade in patients with NAFLD was S1 36%, S2 40% and S3 24%. CAP and 1H-MRS significantly correlated with histopathology and showed comparable accuracy for the detection of hepatic steatosis: areas under the receiver-operating characteristics curves were 0.93 vs. 0.88 for steatosis ≥S1 and 0.94 vs. 0.88 for ≥S2, respectively. Boot-strapping analysis revealed a CAP cut-off of 300 dB/m for detection of S2-3 steatosis, while retaining the lower cut-off of 215 dB/m for the definition of healthy individuals. Direct comparison between CAP and 1H-MRS revealed only modest correlation (total cohort: r = 0.63 [0.44, 0.76]; NAFLD cases: r = 0.56 [0.32, 0.74]). For detection of F2-4 fibrosis TE had sensitivity and specificity of 100% and 98.1% at a cut-off value of 8.85 kPa.

CONCLUSION

Our data suggest a comparable diagnostic value of CAP and 1H-MRS for hepatic steatosis quantification. Combined with the simultaneous TE fibrosis assessment, CAP represents an efficient method for non-invasive characterization of NAFLD. Limited correlation between CAP and 1H-MRS may be explained by different technical aspects, anthropometry, and presence of advanced liver fibrosis.

摘要

引言

在非酒精性脂肪性肝病(NAFLD)中,对脂肪变性和纤维化进行无创评估的相关性日益增加。氢质子磁共振波谱(1H-MRS)和基于超声的受控衰减参数(CAP)与经活检证实的脂肪变性相关,但到目前为止两者尚未相互关联。因此,我们对这两种方法进行了直接比较。

方法

对50例经活检证实为NAFLD的患者和15名健康志愿者进行了1H-MRS和包括CAP的瞬时弹性成像(TE)评估。根据受影响肝细胞的百分比定义脂肪变性:S1为5%-33%,S2为34%-66%,S3≥67%。

结果

NAFLD患者的脂肪变性分级为S1占36%,S2占40%,S3占24%。CAP和1H-MRS与组织病理学显著相关,并且在检测肝脂肪变性方面显示出相当的准确性:对于脂肪变性≥S1,受试者操作特征曲线下面积分别为0.93和0.88;对于≥S2,分别为0.94和0.88。自举分析显示,检测S2-3脂肪变性的CAP临界值为300 dB/m,而对于健康个体的定义,保留较低的临界值215 dB/m。CAP和1H-MRS之间的直接比较仅显示出适度的相关性(总队列:r = 0.63 [0.44, 0.76];NAFLD病例:r = 0.56 [0.32, 0.74])。对于检测F2-4纤维化,TE在临界值8.85 kPa时的敏感性和特异性分别为100%和98.1%。

结论

我们的数据表明,CAP和1H-MRS在肝脂肪变性定量方面具有相当的诊断价值。结合同时进行的TE纤维化评估,CAP是一种对NAFLD进行无创特征描述的有效方法。CAP和1H-MRS之间有限的相关性可能由不同的技术方面、人体测量学以及晚期肝纤维化的存在来解释。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b194/3956815/d5b0f879b3b2/pone.0091987.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b194/3956815/578d0c77da64/pone.0091987.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b194/3956815/4d6a3d6d8dc7/pone.0091987.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b194/3956815/6f7cb105667c/pone.0091987.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b194/3956815/d5b0f879b3b2/pone.0091987.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b194/3956815/578d0c77da64/pone.0091987.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b194/3956815/4d6a3d6d8dc7/pone.0091987.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b194/3956815/6f7cb105667c/pone.0091987.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b194/3956815/d5b0f879b3b2/pone.0091987.g004.jpg

相似文献

1
Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy.使用受控衰减参数和1H-磁共振波谱对非酒精性脂肪性肝病患者的肝脂肪变性进行无创评估。
PLoS One. 2014 Mar 17;9(3):e91987. doi: 10.1371/journal.pone.0091987. eCollection 2014.
2
Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography.使用受控衰减参数(CAP)和瞬时弹性成像技术进行非侵入性诊断肝脂肪变性。
Liver Int. 2012 Jul;32(6):911-8. doi: 10.1111/j.1478-3231.2012.02820.x.
3
Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease.用于非酒精性脂肪性肝病中肝脂肪变性检测和定量的受控衰减参数
J Gastroenterol Hepatol. 2014;29(7):1470-6. doi: 10.1111/jgh.12557.
4
Novel reliability criteria for controlled attenuation parameter assessments for non-invasive evaluation of hepatic steatosis.新型肝脂肪变无创评估的受控衰减参数检测可靠性标准。
United European Gastroenterol J. 2020 Apr;8(3):321-331. doi: 10.1177/2050640619900820. Epub 2020 Jan 17.
5
Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients.中国患者肝脏脂肪变性非侵入性评估的受控衰减参数
World J Gastroenterol. 2014 Apr 28;20(16):4702-11. doi: 10.3748/wjg.v20.i16.4702.
6
Estimating steatosis and fibrosis: Comparison of acoustic structure quantification with established techniques.评估脂肪变性和纤维化:声学结构定量与现有技术的比较。
World J Gastroenterol. 2015 Apr 28;21(16):4894-902. doi: 10.3748/wjg.v21.i16.4894.
7
Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease.用于非酒精性脂肪性肝病中脂肪变性诊断的受控衰减参数
J Gastroenterol Hepatol. 2016 Apr;31(4):848-55. doi: 10.1111/jgh.13219.
8
Ultrasound and FibroScan Controlled Attenuation Parameter in patients with MAFLD: head to head comparison in assessing liver steatosis.超声及 FibroScan 受控衰减参数在 MAFLD 患者中的应用:头对头比较评估肝脏脂肪变。
Endocrine. 2022 Nov;78(2):262-269. doi: 10.1007/s12020-022-03157-x. Epub 2022 Aug 18.
9
Controlled attenuation parameter for the assessment of liver steatosis in comparison with liver histology: a single-centre real life experience.控制衰减参数评估肝脂肪变性与肝组织学的比较:单中心真实经验。
Swiss Med Wkly. 2019 Apr 26;149:w20077. doi: 10.4414/smw.2019.20077. eCollection 2019 Apr 22.
10
Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.肝纤维化无创诊断技术评估非酒精性脂肪性肝病患者肝脏脂肪变及纤维化的准确性。
Gastroenterology. 2019 May;156(6):1717-1730. doi: 10.1053/j.gastro.2019.01.042. Epub 2019 Jan 25.

引用本文的文献

1
Pediatric MASLD: current understanding and practical approach.小儿 MASLD:当前认识与实用方法。
Eur J Pediatr. 2024 Nov 19;184(1):29. doi: 10.1007/s00431-024-05848-1.
2
ANN uncertainty estimates in assessing fatty liver content from ultrasound data.人工神经网络在通过超声数据评估脂肪肝含量中的不确定性估计。
Comput Struct Biotechnol J. 2024 Oct 1;24:603-610. doi: 10.1016/j.csbj.2024.09.021. eCollection 2024 Dec.
3
Evaluation of the Diagnostic Utility of Selected Serum Adipokines and Cytokines in Subjects with MASLD-A Pilot Study.

本文引用的文献

1
Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population.控制衰减参数(CAP)在慢性肝病患者肝脂肪变性检测中的应用:一项对韩国本地人群的前瞻性研究。
Liver Int. 2014 Jan;34(1):102-9. doi: 10.1111/liv.12282. Epub 2013 Sep 13.
2
Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification.非酒精性脂肪性肝病:无创性检查和危险分层。
J Clin Pathol. 2013 Dec;66(12):1033-45. doi: 10.1136/jclinpath-2013-201620. Epub 2013 Aug 12.
3
Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease.
评价 MASLD 患者中部分血清脂肪因子和细胞因子的诊断效用:一项初步研究。
Nutrients. 2024 May 2;16(9):1381. doi: 10.3390/nu16091381.
4
Gut Microbiome-How Does Two-Month Consumption of Fiber-Enriched Rolls Change Microbiome in Patients Suffering from MASLD?肠道微生物群——食用富含纤维的面包两个月如何改变患有代谢功能障碍相关脂肪性肝病(MASLD)患者的微生物群?
Nutrients. 2024 Apr 15;16(8):1173. doi: 10.3390/nu16081173.
5
Relationship between skeletal muscle mass loss and metabolic dysfunction-associated fatty liver disease among Chinese patients with metabolic dysregulation.代谢失调中国患者骨骼肌质量损失与代谢功能相关脂肪性肝病的关系。
Rev Assoc Med Bras (1992). 2024 Mar 4;70(3):e20230963. doi: 10.1590/1806-9282.20230963. eCollection 2024.
6
Predictive Algorithm for Hepatic Steatosis Detection Using Elastography Data in the Veterans Affairs Electronic Health Records.利用退伍军人事务部电子健康记录中的弹性成像数据检测肝脂肪变性的预测算法。
Dig Dis Sci. 2023 Dec;68(12):4474-4484. doi: 10.1007/s10620-023-08043-8. Epub 2023 Oct 21.
7
Muscle Mass Adjusted for Body Weight Is Associated with Significant Liver Fibrosis in Young Adults with Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study from a Korean Military Hospital.体重校正后的肌肉量与非酒精性脂肪性肝病年轻成人的显著肝纤维化相关:来自韩国一家军事医院的横断面研究。
J Obes Metab Syndr. 2023 Sep 30;32(3):279-283. doi: 10.7570/jomes23035. Epub 2023 Sep 4.
8
The Accuracy of Ultrasound Controlled Attenuation Parameter in Diagnosing Hepatic Fat Content.超声控制衰减参数诊断肝脏脂肪含量的准确性
Hepat Med. 2023 Jun 9;15:51-61. doi: 10.2147/HMER.S411619. eCollection 2023.
9
Circulating levels of endotrophin and cross-linked type III collagen reflect liver fibrosis in people with HIV.循环内毒素和 III 型胶原交联水平反映了 HIV 感染者的肝纤维化。
BMC Infect Dis. 2023 Jan 24;23(1):52. doi: 10.1186/s12879-023-08000-w.
10
Precision Nutrition in NAFLD: Effects of a High-Fiber Intervention on the Serum Metabolome of NAFD Patients-A Pilot Study.非酒精性脂肪性肝病的精准营养:高纤维干预对非酒精性脂肪性肝病患者血清代谢组的影响——一项初步研究。
Nutrients. 2022 Dec 16;14(24):5355. doi: 10.3390/nu14245355.
简单的无创系统可预测非酒精性脂肪性肝病患者的长期预后。
Gastroenterology. 2013 Oct;145(4):782-9.e4. doi: 10.1053/j.gastro.2013.06.057. Epub 2013 Jul 13.
4
Gastrointestinal complications of obesity: non-alcoholic fatty liver disease (NAFLD) and its sequelae.肥胖相关的胃肠道并发症:非酒精性脂肪性肝病(NAFLD)及其后果。
Best Pract Res Clin Endocrinol Metab. 2013 Apr;27(2):195-208. doi: 10.1016/j.beem.2013.02.002. Epub 2013 Mar 1.
5
Transient elastography: Kill two birds with one stone?瞬时弹性成像:一石二鸟?
World J Hepatol. 2013 May 27;5(5):264-74. doi: 10.4254/wjh.v5.i5.264.
6
The predictive value of steatosis in hepatitis C virus infection.脂肪变性在丙型肝炎病毒感染中的预测价值。
Expert Rev Gastroenterol Hepatol. 2013 Mar;7(3):205-13. doi: 10.1586/egh.13.7.
7
Controlled attenuation parameter for non-invasive assessment of hepatic steatosis: does etiology affect performance?控制衰减参数用于无创性评估肝脂肪变性:病因是否影响其性能?
J Gastroenterol Hepatol. 2013 Jul;28(7):1194-201. doi: 10.1111/jgh.12134.
8
Software for automated MRI-based quantification of abdominal fat and preliminary evaluation in morbidly obese patients.基于 MRI 的腹部脂肪自动定量软件及其在病态肥胖患者中的初步评估。
J Magn Reson Imaging. 2013 May;37(5):1144-50. doi: 10.1002/jmri.23890. Epub 2012 Nov 2.
9
Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease.使用 XL 探头测量非酒精性脂肪性肝病患者的肝硬度。
Am J Gastroenterol. 2012 Dec;107(12):1862-71. doi: 10.1038/ajg.2012.331. Epub 2012 Oct 2.
10
Best single-slice measurement site for estimating visceral adipose tissue volume after weight loss in obese, Japanese men.肥胖日本男性减肥后估算内脏脂肪组织体积的最佳单一切面测量部位。
Nutr Metab (Lond). 2012 Jun 14;9:56. doi: 10.1186/1743-7075-9-56.